Advertisement
Advertisement

IRWD

IRWD logo

Ironwood Pharmaceuticals, Inc. - Class A

3.63
USD
Sponsored
+0.28
+8.36%
Jun 11, 15:58 UTC -4
Closed
exchange

Pre-Market

3.67

+0.04
+1.24%

Ironwood Pharmaceuticals, Inc. - Class A Profile

About

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

Info & Links

CEO

Thomas McCourt

Headquarters

100 SUMMER STREET, SUITE 2300
BOSTON, MA 02110, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.ironwoodpharma.com

Auditor

KPMG LLP

Share holders

29

Employees

100

Ironwood Pharmaceuticals, Inc. - Class A Statistics

Valuation Measures

Market Capitalization2

604.95M

Enterprise Value

969.34M

Enterprise Value/EBITDA(ttm)

4.80

Price to Earnings Ratio(ttm)

15.65

Price to Sales(ttm)

1.98

Price to Book(mrq)

--

Price to Cash(ytd)

13.99

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

13.52%

Profit Margin(ttm)

-8.78%

Return on Equity(ttm)

-13.72%

Return on Invested Capital(ttm)

47.08%

Return on Assets(ttm)

10.95%

Income Statement

Revenue(ttm)

361.51M

Revenue Per Share(ttm)

2.20

Gross Profit(ttm)

361.51M

EBITDA(ttm)3

202.03M

Net Income Available to Common(ttm)

102.18M

Diluted EPS(ttm)

0.13

Share Statistics

Beta (5Y Monthly)

0.17

52-Week Change

402.98%

S&P 500 52-Week Change

22.32%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

164.61M

Dividend Yield

0.00%

Float4

142.35M

% Held by Insiders

12.70%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

220.47M

Total Cash Per Share(mrq)

1.34

Total Debt(mrq)

584.86M

Total Debt/Equity(mrq)

-223.30%

Current Ratio(mrq)

1.13%

Quick Ratio(mrq)

1.13%

Book Value Per Share(mrq)

-1.61

Cash Flow

Operating Cash Flow Per Share(ytd)

0.78

Free Cash Flow(ytd)

127.01M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement